Objective  To systematically evaluate the pharmacoeconomic value of copanlisib hydrochloride for injection combined with rituximab in the treatment of relapsed/refractory non-Hodgkin lymphoma (R/R NHL).

Methods  From the perspective of China's healthcare service system, a partitioned survival model was constructed. Survival data were referred to a phase Ⅲ clinical study; utility values for different survival states were cited from pharmacoeconomic research literature on similar diseases; and the data were combined with the actual diagnosis and treatment costs in Chinese hospitals. The incremental cost-utility ratio (ICUR) was calculated and compared with the annual willingness-to-pay (WTP) threshold of three times the per capita gross domestic product (GDP). The robustness of the results was verified through one-way sensitivity analysis and probabilistic sensitivity analysis.

Results  Compared with rituximab monotherapy, the incremental cost-utility ratio of the copanlisib hydrochloride for injection combined with the rituximab group was -1,464,428 yuan per quality-adjusted life years (QALYs). The results of one-way sensitivity analysis showed that the top three parameters with the greatest impact on the economic results were: utility value in the disease progression state, unit cost of copanlisib hydrochloride, and discount rate for health outcomes. The results of probabilistic sensitivity analysis showed that under the set WTP threshold, the probability of the economic advantage of the rituximab monotherapy regimen was 100%, indicating that the evaluation results were robust.

Conclusion  At present, the regimen of copanlisib hydrochloride combined with rituximab for the treatment of relapsed/refractory non-Hodgkin lymphoma does not yet have pharmacoeconomic rationality.

1.Miranda-Filho A, Piñeros M, Znaor A, et al. Global patterns and trends in the incidence of non-Hodgkin lymphoma[J]. Cancer Causes Control, 2019, 30(5): 489-499. DOI: 10.1007/s10552-019-01155-5.

2.Juárez-Salcedo LM, Conde-Royo D, Quiroz-Cervantes K, et al. Use of anti-CD20 therapy in follicular and marginal zone lymphoma: a review of the literature[J]. Drugs Context, 2020, 9: 2019-9-3. DOI: 10.7573/dic.2019-9-3.

3.Salles G, Barrett M, Foà R, et al. Rituximab in B-cell hematologic malignancies: a review of 20 years of clinical experience[J]. Adv Ther, 2017, 34(10): 2232-2273. DOI: 10.1007/s12325-017-0612-x.

4.孙雨田, 张清媛. Copanlisib治疗复发或难治性滤泡性淋巴瘤的研究进展[J]. 癌症进展, 2020, 18(11): 1089-1091. [Sun YT, Zhang QY. Progress of copanlisib in the treatment of relapsed or refractory follicular lymphoma[J]. Oncology Progress, 2020, 18(11): 1089-1091.] DOI: 10.11877/j.issn.1672-1535.2020.18.11.03.

5.初文慧, 高娜, 刘增艳, 等. 滤泡性淋巴瘤的治疗进展[J]. 中国医学创新, 2024, 21(13): 162-167. [Chu WH, Gao N, Liu  ZY, et al. Therapeutic progress of follicular lymphoma[J]. Medical Innovation of China, 2024, 21(13): 162-167.] DOI: 10.3969/j.issn.1674-4985.2024.13.037.

6.Matasar MJ, Capra M, Özcan M, et al. Copanlisib plus rituximab versus placebo plus rituximab in patients with relapsed indolent non-Hodgkin lymphoma (CHRONOS-3): a double-blind, randomised, placebo-controlled, phase 3 trial[J]. Lancet Oncol, 2021, 22(5): 678-689. DOI: 10.1016/s1470-2045(21)00145-5.

7.曾小慧, 彭六保, 谭重庆,等. 药物经济学评价中的分区生存模型[J]. 中国新药与临床杂志, 2020, 39(8): 504-507. [Zeng XH, Peng LB, Tan CQ, et al. Partitioned survival model in pharmacoeconomics[J]. Chinese Journal of New Drugs and Clinical Remedies, 2020, 39(8): 504-507.] DOI: 10.14109/j.cnki.xyylc.2020.08.12.

8.孟蕊, 芮明军, 王欣恬, 等. 不同决策分析模型在抗肿瘤药物经济学评价中的应用——以加拿大CADTH为例[J]. 中国药房, 2021, 32(14): 1752-1757. [Meng R, Rui MJ, Wang  XT, et al. Application of different decision analysis models in the economic evaluation of antitumor drugs: taking CADTH in canada as an example[J]. China Pharmacy, 2021, 32(14): 1752-1757.] DOI: 10.6039/j.issn.1001-0408.2021.14.15.

9.梁锦莹, 张炜晨, 余美辰, 等. 维泊妥珠单抗联合RCHP用于治疗初诊弥漫性大B细胞淋巴瘤的成本-效用[J]. 中国药物经济学, 2024, 19(4): 17-23. [Liang JY, Zhang WC, Yu MC, et al. Cost-utility of polatuzumab vedotin combination with RCHP for the treatment of previously untreated diffuse large B-cell lymphoma[J]. China Journal of Pharmaceutical Economics, 2024, 19(4): 17-23.] DOI: 10.12010/j.issn.1673-5846.2024.04.003.

10.苏展, 车金辉, 裴锐锋. 替雷利珠单抗较索拉非尼作为晚期不可切除肝细胞癌一线治疗的成本-效用分析[J]. 中国药师, 2024, 27(1): 109-116. [Su Z, Che JH, Pei RF. Cost-utility analysis of tislelizumab versus sorafenib as first-line treatment for advanced unresectable hepatocellular carcinoma[J]. Chinese Pharmacist, 2024, 27(1): 109-116.] DOI: 10.12173/j.issn.1008-049X.202312216.

11.Zhang JZ, Rios JD, Pechlivanoglou T, et al. SurvdigitizeR: an algorithm for automated survival curve digitization[J]. BMC Med Res Methodol, 2024, 24(1): 147. DOI: 10.1186/s12874-024-02273-8.

12.Latimer NR. Survival analysis for economic evaluations alongside clinical trials-extrapolation with patient-level data: inconsistencies, limitations, and a practical guide[J]. Med Decis Making, 2013, 33(6): 743-754. DOI: 10.1177/0272989X12472398.

13.石丰豪, 李薇, 韩晟. 泽布替尼治疗复发和难治套细胞淋巴瘤的成本-效用分析[J]. 中国研究型医院, 2022, 9(5): 29-34. [Shi FH, Li W, Han S. Cost-utility analysis of zanubrutinib in the treatment of relapsed and refractory adult mantle cell lymphoma[J]. Journal of Chinese Research Hospitals, 2022, 9(5): 29-34.] DOI: 10.19450/j.cnki.jcrh.2022.05.006.

14.曾启, 包健安, 马晶晶. 奈达铂对比顺铂用于晚期肺鳞癌化疗的药物经济学评价[J]. 中国药物经济学, 2023, 18(9): 21-25. [Zeng Q, Bao JA, Ma JJ. Cost-effectiveness of nedaplatin plus docetaxel versus cisplatin plus docetaxel for chemotherapy in advanced or relapsed squamous non-small cell lung cancer[J]. China Journal of Pharmaceutical Economics, 2023, 18(9): 21-25.] DOI: 10.12010/j.issn.1673-5846.2023.09.004.

15.沈斌, 李园, 陆晓蕾, 等. 蒽环类药物治疗非霍奇金淋巴瘤的药物经济学研究[J]. 临床药物治疗杂志, 2020, 18(10): 20-23. [Shen B, Li Y, Lu XL, et al. Pharmacoeconomic study of anthracycline in the treatment of non-Hodgkin's lymphoma[J]. Clinical Medication Journal, 2020, 18(10): 20-23.] DOI: 10.3969/j.issn.1672-3384.2020.10.005.

16.Tappenden P, Simpson E, Hamilton J, et al. Ibrutinib for treating relapsed or refractory mantle cell lymphoma: an evidence review group perspective of a NICE single technology appraisal[J]. Pharmacoeconomics, 2019, 37(3): 333-343. DOI: 10.1007/s40273-018-0713-7.

17.贾欣欣, 徐玲, 张耀光, 等. 中国≥15岁居民常见慢性病患病现状及其对生命质量影响[J]. 中国公共卫生, 2017, 33(11): 1567-1570. [Jia XX, Xu L, Zhang YG, et al. Prevalence of common chronic diseases and its influences on health-related quality of life among general population aged 15 years and over in China[J]. China Public Health, 2017, 33(11): 1567-1570.] DOI: 10.11847/zgggws2017-33-11-07.

18.Dreyling M, Morschhauser F, Bouabdallah K, et al. Phase II study of copanlisib, a PI3K inhibitor, in relapsed or refractory, indolent or aggressive lymphoma[J]. Ann Oncol, 2017, 28(9): 2169-2178. DOI: 10.1093/annonc/mdx289.

19.Tang X, Chen X, Zhang T, et al. Copanlisib plus rituximab combination therapy vs. rituximab monotherapy for relapsed indolent non-Hodgkin lymphoma: a cost-effectiveness analysis[J]. Ann Transl Med, 2022, 10(6): 352. DOI: 10.21037/atm-22-1159.

20.Mozas P, Sorigué M, López-Guillermo A. Follicular lymphoma: an update on diagnosis, prognosis, and management[J]. Med Clin (Barc), 2021, 157(9): 440-448. DOI: 10.1016/j.medcli.2021.03.041.